Aquestive Therapeutics (NASDAQ:AQST) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note released on Wednesday morning, Benzinga reports. The brokerage currently has a $9.00 price objective on the stock. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.57) EPS.

A number of other research analysts have also issued reports on the stock. SVB Leerink initiated coverage on shares of Aquestive Therapeutics in a research note on Friday, May 10th. They set an outperform rating and a $8.00 price target on the stock. Leerink Partnrs raised Aquestive Therapeutics to a strong-buy rating in a research report on Friday, May 10th. Finally, JMP Securities restated a market outperform rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research note on Monday, August 12th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and an average target price of $7.83.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $4.24 on Wednesday. The stock’s fifty day moving average price is $3.03 and its 200 day moving average price is $3.42. Aquestive Therapeutics has a 1-year low of $1.25 and a 1-year high of $6.23. The company has a market cap of $386.01 million, a price-to-earnings ratio of -10.10 and a beta of 2.80.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.08. The business had revenue of $20.10 million during the quarter, compared to analyst estimates of $12.62 million. During the same period in the prior year, the business posted ($0.10) EPS. As a group, equities research analysts anticipate that Aquestive Therapeutics will post -0.49 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AQST. Victory Capital Management Inc. purchased a new position in shares of Aquestive Therapeutics during the 2nd quarter valued at about $27,000. SG Americas Securities LLC acquired a new stake in Aquestive Therapeutics during the first quarter worth about $54,000. Jump Financial LLC purchased a new position in Aquestive Therapeutics during the fourth quarter valued at approximately $60,000. The Manufacturers Life Insurance Company acquired a new position in Aquestive Therapeutics in the second quarter valued at approximately $76,000. Finally, Financial Advocates Investment Management lifted its holdings in Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after acquiring an additional 14,000 shares during the period. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.